Lunai Bioworks Expands CNS Platform with $20M Equity Issuance

Lunai Bioworks completes a $20 million preferred equity issuance to acquire intellectual property assets, addressing limitations in neurological disease treatment and supporting the development of targeted therapeutic combinations.